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Effects of parathyroidectomy on bone formation and mineralization in
hemodialyzed patients. Undecalcified sections of doubly tetracycline-
labeled transiliac bone biopsy specimens obtained from ten hemodia-
lyzed patients before and 10 to 16 months after parathyroidectomy
(PTX) were analyzed. Before parathyroidectomy (total PTX with
autotranspiant in six patients and subtotal PTX in four patients), all the
patients demonstrated histological evidence of hyperparathyroidism
with increased resorption parameters. A high bone formation rate
(BFR) was noted in all patients but one who had both an increase in the
osteoid seam thickness and a low calcification rate characteristic of
osteomalacia. A significant correlation was found between im-
munoreactive parathyroid hormone (iPTH) levels and BFR at the tissue
and at the basic multicellular unit (BMU) levels. Parathyroidectomy
was associated with a dramatic drop in resorption surfaces and
osteoclast number as well as in bone formation rate at the tissue, BMU,
and cell-levels. After PTX, the bone formation rate at the tissue level
was low or in the lower range of normal values in six patients. The
thickness index of osteoid seams was significantly reduced and no
evidence of osteomalacia was present even in the six patients showing
bone aluminum deposits after PTX. One of the three patients, who had
an iPTH level within the normal range after PTX, showed an osteoid
excess associated with a low bone formation rate. These data demon-
strate that increased PTH secretion is an important factor of bone
formation in dialyzed patients and that excessive reduction of the PTH
secretion leads to an inactive bone.
Effets de Ia parathyroidectomie sur Ia formation et Ia mineralisation
osseuses chez des malades hemodialyses. Les coupes non décalcifiées de
biopsies osseuses transiliaques prdlevées après double marquage a Ia
tetracycline chez dix malades hémodialysés avant et 10 a 16 mois après
parathyroidectomie (PTX) ont etC analysdes. Avant parathyroidectomie
(PTX totale avec autotransplantation chez six malades etPTX subtotale
chez quatre malades), tous les malades prCsentaient des signes
histologiques d'hyperparathyroidisme avec augmentation des
paramètres de resorption. La vitesse de formation osseuse (BFR) Ctait
ClevCe chez tours les malades sauf un qui avait a la fois une augmentation
de l'Cpaisseur des bordures ostCoides et une vitesse de calcification
basse, caractCristiques d'une ostComalacie. Une correlation significa-
tive a etC trouvCe entre les niveaux d'hormone parathyroidienne
immunorCactive (iPTH) et de BFR au niveau du tissu et des unites
multicellulaires de base (BMU). La parathyroidectomie s'est associCe a
une reduction trCs importante des surfaces de resorption et du nombre
d'ostCoclastes, ainsi que de Ia vitesse de formation osseuse au niveau
du tissu, des BMU et des cellules. AprCs PTX, la vitesse de Ia formation
osseuse au niveau tissulaire dtait basse, ou a la limite inférieure de la
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normale chez six malades. L'indice d'epaisseur des bordures ostCoides
Ctait significativement rCduit et aucun signe d'ostComalacie n'Ctait
present, mCme chez les six malades prCsentant des depots osseux
d'aluminium aprés PTX. Un des trois malades ayant un taux normal de
iPTH aprCs PTX avait cependant un excCs d'ostCoide associé a une
vitesse de formation osseuse basse. Ces donnCes dCmontrent que
l'élCvation de la sCcrCtion de PTH est un facteur important de formation
osseuse chez les hemodialysés et qu'une reduction excessive de la
sécrCtion de PTH conduit a un os inactif.
Secondary hyperparathyroidism (HPT) remains a frequent
complication of chronic renal failure despite an improved
understanding of the factors responsible for its development [1].
The prolonged survival of patients with dialysis results in a
growing number of uremic patients suffering from severe HPT
responsible not only for major bone lesions but also for an
impairment of vital functions [21. Calcium supplement, phos-
phate binders, and vitamin D metabolite administration have
demonstrated their efficacy in the prevention and treatment of
secondary HPT in chronic renal failure [3, 4]. But vitamin D
metabolites may be difficult to administer and inconsistently
effective in patients demonstrating severe HPT because of
hypercalcemia and/or uncontrolled hyperphosphatemia. Thus,
a surgical reduction of the parathyroid gland mass may become
necessary when medical treatment fails [5].
Successful parathyroidectomy (PTX) is usually followed by
the improvement of clinical and radiological evidence of HPT.
However, the possible development of spontaneous fractures
after PTX has been recently reported [6]. In these patients,
biochemical and x-ray evidence of HPT was present before
PTX but clinical and radiological symptoms of osteomalacia
(OM) were lacking. Unfortunately, no undecalcified bone bi-
opsy specimen was available prior to the PTX in these reports
[6, 7], with one exception [61, to exclude an osteomalacia
pre-existent to the PTX. It is thus difficult to accurately
determine the bone changes induced by PTX especially in the
bone mineralization process.
We report herein a histomorphometric study of iliac bone in
hemodialyzed patients before and after parathyroidectomy to
analyze the bone changes following a PTX.
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Table 1. Clinical data in hemodialyzed patients who underwent a parathyroidectomy (PTX)
Aluminum
Patient Kidney
Dialysis
duration
before PTX
hydroxide
giday
Interval
between PTX
and second
no. Age Sex disease months PTX A B biopsy, months
1 50 M CIN 55 Total +
autotransplantation
8 2 13
2 28 M CIN 73 Total +
autotransplantation
1 0 14
3 52 F PCK 132 Subtotal 9 6 14
4 48 M NAS 61 Subtotal 3 6 14
5 20 M CGN 96 Total +
autotranspiantation
6 8 16
6 56 F CIN 5 Total +
autotransplantation
2 0 12
7 57 F CIN 28 Total +
autotranspiantation
6 5 16
8 37 F CGN 47 Total +
autotranspiantation
3 6 12
9 24 F AM 31 Subtotal 7.5 1.5 10
10 49 M CGN 38 Subtotal 6.5 6 10
Abbreviations: CIN, chronic interstitial nephritis; PCK, polycystic kidneys; NAS, nephroangiosclerosis; AM, amyloidosis; A, at the time of the
first bone biopsy; B, at the time of the second bone biopsy.
Methods
Patients
Five females and five males, aged 20 to 57 years (mean, 42
14 years) with chronic renal failure of miscellaneous origin were
investigated (Table 1). They were on maintenance hemodialysis
from 5 to 132 months (mean, 57 37 months) and underwent a
parathyroidectomy. A total PTX with autotransplantation in the
forearm was performed in six patients and a subtotal PTX was
done in four patients. In three of these latter patients, three and
one-half hyperplastic parathyroid glands were removed and in
patient 10 only two markedly enlarged glands were removed.
PTX was performed because patients demonstrated biochemi-
cal or x-ray evidence of HPT.
Before parathyroidectomy, all patients were receiving oral
aluminum hydroxide at a mean daily dose of 5.2 2.8 g. None
of the patients except patient 9 received calcium and vitamin D
supplementation during the 3 months prior to the PTX. Patient
9 received an oral calcium supplementation (500 mg124 hr) and
l-25(OH)2 vitamin D (0.25 g/24 hr) for 2 months between the
first bone biopsy and the PTX. This therapy was withdrawn 7
weeks before the PTX because of hypercalcemia. No patient
received anticonvulsant therapy; only patient 9 received an oral
treatment with corticosteroids for 7 years (cortivazol acetate at
0.8 mg/24 hr; dose equivalent to 10 mg/24 hr of prednisone) for
chronic juvenile arthritis.
At the time of the parathyroidectomy, the dialysis (4 or 5 hr
three times each week) were conducted using water treated
with reverse osmosis in four patients and softened water in six
patients. At that time, aluminum concentration of the water was
measured in nine patients (Table 2). The concentrations of
calcium and magnesium of the dialysate were 7.0 and 1.8 mgldl,
respectively.
After the parathyroidectomy, patients were supplemented
with oral calcium (patients 1, 2, 4, 5, 9, and 10) and vitamin D
metabolites (250HD3 in patient 3; 1 a-OHD3 in patients 6, 8, 9,
and 10 and a combination of these two vitamin D compounds in
patients 1, 2, 4, and 5) at doses necessary to maintain serum
calcium values within the normal range. In addition, all the
patients except patient 2 received aluminum hydroxide at
varying doses to maintain predialysis serum phosphorus level
below 6.0 mg/dl. At the time of the second bone biopsy, the
mean daily dose of aluminum hydroxide given to patients was
4.1 2.9 g (not significantly different from pre-PTX values).
Bone histomorphometry
A horizontal transiliac bone biopsy was taken from each
patient using a 7.5-mm inner diameter trephine before and 10 to
16 months after PTX. The first bone biopsy was done the day of
the PTX in patients 1 to 8. In patients 9 and 10 bone biopsy
specimens were taken 4 and 5 months, respectively, prior to the
PTX. A tetracycline double labeling was performed prior to
each bone biopsy with 600 mg124 hr of demethylchlortetracy-
dine administered according to the schedule: 2 days on, 12 days
off, and then 4 days on. The biopsy specimen was taken 3 to 10
days after the end of the second tetracycline labeling. The bone
specimens were processed without decalcification and embed-
ded in methylmetacrylate. Measurements were made on serial
nonconsecutive 8-sm thick sections stained by Solochrome
Cyanin® (BDH Chemicals Ltd, Poole, England) for osteoid
parameters and by Goldner's method for resorption param-
eters. Twenty-micron thick unstained sections were used for
the measurement of tetracycline-labeled surfaces and calcifica-
tion rate under ultraviolet light. Bone surfaces and volumes
were measured by linear intercept and point counting tech-
niques using a Merz grid. The following parameters were
measured:
Static parameters
• The trabecular bone volume (TBV) was expressed as the
percentage of trabecular bone tissue in the total spongy bone
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space. It was measured on four sections. The results were
compared to the mean normal value calculated from 147 control
subjects aged from 20 to 58 years; all suffered sudden death [81.
• The total osteoclastic resorption surfaces (TRS) were ex-
pressed as the percentage of the total trabecular surfaces, and
were defined as scalloped surfaces with or without osteoclasts.
Normal TRS values did not change with age and sex in 130
controls [91.
• The osteoclast number (OCl) per square millimeter of
spongiosal tissue was measured on the same sections as resorp-
tion surfaces. The measured values were compared with normal
values obtained from Rasmussen and Bordier [10].
• The relative trabecular osteoid volume (TOV) represents
the percentage of total trabecular bone tissue occupied by
osteoid measured on four sections.
• The relative trabecular osteoid surfaces (TOS) represent
the percentage of total trabecular surface covered with osteoid.
They were measured by using the same method as the one used
for TRS measurement.
• The thickness index of osteoid seams (TIOS) represents the
ratio (osteoid volume/osteoid surfaces) times 100 which validly
estimates the true thickness of osteoid seams [11]. This param-
eter does not change with age or sex.
Mean values of TOY, TOS, and TIOS were compared with
those obtained from 72 age and sex-matched control subjects
[121.
• The osteoblastic surfaces (OblS) were expressed as the
percentage of total trabecular surfaces lined by well-differenti-
ated osteoblasts and were measured on two Toluidine blue-
stained sections.
• The osteoblastic osteoid surfaces were the percentage of
osteoid surfaces lined by well-differentiated osteoblasts.
• Fibrotic surfaces were only estimated by a semiquantitative
method according to their extent: +, + +, and + + +.
Dynamic parameters
• Single-labeled surfaces (SLS) were expressed as the per-
centage of the total trabecular surfaces showing single tetra-
cycline labels.
• Double-labeled surfaces (DLS) were expressed as the per-
centage of the total trabecular surfaces showing double labels.
• Total labeled surfaces (TLS) were DLS + SLS. The
measured values were compared with normal values obtained
from Nielsen, Melsen, and Christensen [131.
• Double-labeled osteoid surfaces (DLOS) were expressed as
the percentage of osteoid surfaces showing double labels
(DLOS:DLS/TOS).
• Single-labeled osteoid surfaces (SLOS) were the percent-
age of osteoid surfaces showing single labels (SLOS =
SLS/TOS) and total labeled osteoid surfaces (TLOS = SLOS
+ DLOS).
• The calcification rate (CR) was determined by dividing the
average distance between the two tetracycline labels (in m) by
the time interval between the labeling period (15 days). CR was
therefore expressed in tm/24 hr, uncorrected for oblique cut-
ting.
The double- and single-labeled fluorescent sites were mea-
sured on four sections.
• The bone formation rate at the tissue level (BFR tissue)
which represents the amount of mineralized bone being made
per unit surface area of trabecular bone per day was expressed:
BFR tissue = CR x TLS (jm3/m2/24 hr). The measured
values were compared with normal values from Nielsen,
Melsen, and Christensen [13].
• The bone formation rate at the basic multicellular unit
(BFRBMU) represents the amount of mineralized bone being
made per day per unit osteoid-covered surfaces. It was calcu-
lated as (CR x TLS)ITOS and expressed in m3/m2/24 hr.
Aluminum staining procedure
Three 8-sm thick sections were stained in aurine
tricarboxylic acid (Aluminon) solution according to the method
reported by Maloney et a! [14]. The aluminon buffer solution
was at pH = 5.2 which was reported to give the most reproduc-
ible results [141. Sections were counterstained with methylene
blue. Aluminum deposits appeared to stain as pink or red bands
which were frequently localized at the interface between min-
eralized bone and osteoid tissue, at the apparently neutral
surfaces or inside the calcified bone at the cement lines.
Quantitation of aluminum deposits was performed manually by
measuring the percentage of trabecular surfaces covered with
red bands at the neutral surfaces or at the formation surfaces
(A1S).
Biochemistry
Serum biochemical parameters were measured at the time
bone biopsy specimens were taken:
• Serum calcium (SCa), serum phosphorus (SP), and serum
alkaline phosphatase (SAP) levels were measured by a routine
autoanalyzer method. The normal adult range for SCa was 8.8
to 10.4 mgldl; SP, 2.8 to 4.0 mgldl; SAP, 60 to 200 lU/liter.
• Serum parathyroid hormone (iPTH) determinations were
performed by radioimmunoassays using antisera recognizing
the carboxyl terminal end of the molecule. In patients 1 to 8,
iPTH concentrations before PTX were measured using a guinea
pig antiserum (GP 47 antiserum) kindly provided by Dr. Pea-
cock (Leeds, United Kingdom) and were repeated after PTX
with the same antiserum in seven patients. The normal range is
4 to 25 plEq/ml. In patient 8, post-PTX measurement of iPTH
level was performed with a rabbit antibovine PTH antiserum
[15]. This antiserum was also used for measurements of pre-
and post-PTX values of iPTH in patients 9 and 10. The normal
range with this antiserum is 450 to 1450 pglml. In the six
patients who underwent a total PTX with reimplantation of
parathyroid (PTH) tissue in the forearm, blood samples for PTH
measurements were taken from the nongrafted arm.
• Serum aluminum levels were measured by atomic absorp-
tion spectrophotometry (AAS). To avoid contamination, blood
samples were collected in polypropylene test tubes without
anticoagulant. Blood was centrifugated and serum fraction was
stored in polypropylene tubes at 4°C. For the measurement, a
sixfold dilution of the serum was made with a 0.5% nitric acid
solution. The pipettes used for dilution were maintained in a
chlorhydric acid solution and rinsed with pure water before use.
The AAS apparatus was a spectrophotometer 1L157,
electrothermic atomizer 1L555 (Instrumentation Laboratory,
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Table 2. Individual biochemical parameters before (A) parathyroidectomy and at the time of the second bone biopsy after parathyroidectomy
(B) in hemodialyzed patients
Dialysate
Patient
no.
Before/alter
PTX
SC(N = a, mg/dl8.8 to 10.4)
SP(N = , mg/dl2.8 to 4.0)
SAP
(N = , lU/liter60 to 200)
iPT
(N
H, idEq/ml
= 4 to 25)
SA
(N
1, pg/liter
= 5 to 46)
Al concentration
pg/liter
1 A 8.7 4.5 857 1000 23 23
B 9.9 4.6 100 11.5 9
2 A 10.2 9.4 404 2250 II 20
B 9.2 6.6 80 84 18
3 A 8.7 5.1 132 400 42 2
B 10.6 3.3 176 170 34
4 A 9.7 5.2 260 860 109 115
B 8.5 4.8 115 160 30
5 A 9.4 5.8 488 660 49 2
B 10.4 5.3 120 160 NA
6 A 10.0 1.9 792 960 30 2
B 8.7 3.5 178 165 25
7 A 10.7 5.2 102 120 40 4
B 9.2 3.4 365 90 39
8 A 9.7 4.3 250 1110 85 2
B 8.8 4.9 140 (600) 36
9 A 10.1 4.8 NA (5330) 189 NA
B 9.5 5.9 100 (2630) 115
10 A 10.4 7.8 440 (5780) 299 66
B 10.7 4.3 200 (780) 400
Abbreviations/symbol: NA, not available; SCa, serum calcium; SP, serum phosphorus; SAP, serum alkaline phosphatase; iPTH, serum PTH;
SAl, serum aluminum levels; Al, aluminum; ( ) values of iPTH obtained with a different antibody (normal range, 450 to 1450 pg/mI); PTX,
parathyroidectomy.
Table 3. Mean values (± SD) of serum biochemical parameters before
and after parathyroidectomy (PTX) in hemodialyzed patients
Before
(N =
PTX
10)
After P
(N
TX
10)
Normal
range
Serum calcium,
mg/dl 9.8 0.7 9.6 0.8 8.8 to 10.4
Serum phosphorus,
mg/dl 5.4 2.0 4.7 1.1 2.8 to 4.0
Serum alkaline
phosphatase,
lU/liter 414
P1=
268
9
147 86b 60 to 200
iPTH, plEqimi 893N=
677
7
120N= 60b7
4 to 25
Serum aluminum,
pg/liter 88 91 78 124 5 to 46
a The values were recorded at the time of the second bone biopsy.
b These are different from initial values, with a significance at P <
0.05.
Lexington, Massachusetts, USA). The range of serum alumi-
num in our control population was 5 to 46 pg/liter.
Statistical methods
Statistical methods employed included Student's t test for
mean values, Wilcoxon's T test and Spearman's coefficient of
correlation.
Before parathyroidectomy
Results
Biochemistry. Individual parameters are listed in Table 2 and
mean values (± SD) in Table 3. Serum calcium was spontane-
ously normal or elevated in eight patients and low in two
patients (mean value, 9.8 0.7 mg/dl). The serum phosphorus
level was increased in all patients but one (mean value, 5.4
2.0 mgldl). Serum alkaline phosphatase levels were increased in
seven out of nine patients and serum iPTH concentrations were
substantially elevated in all but patient 7.
Serum aluminum levels ranged from 11 (normal value) to 297
pg/liter (markedly increased value).
Bone histomorphometry. Individual static and dynamic
histomorphometric parameters are listed in Tables 4 and 5,
respectively, and mean values (± SD) are shown in Table 6.
All the patients demonstrated histomorphometric evidence of
severe hyperparathyroidism as shown by a significant increase
in both resorption parameters (extension of resorption surfaces
and osteoclast number per mm2, P < 0.001) and static bone
formation parameters [osteoid volume and osteoid surfaces (P
<0.001) and osteoblastic surfaces]. Dynamically, total labeled
surfaces were also increased (P <0.001) as was the trabecular
calcification rate (P < 0.05). The thickness index of osteoid
seams was significantly greater than normal (P < 0.01). Patient
7, whose serum PTH level was only slightly increased, had an
increased osteoid seam thickness associated with a decreased
calcification rate characteristic of osteomalacia. Three other
patients, 1, 4, and 9, however, had a relative delay in the
mineralization as shown by an increased TIOS and a calcifica-
tion rate which was within the normal range. Bone formation
rate at the tissue level was significantly increased (P < 0.001)
when compared to normal values from Nielsen, Melsen, and
Christensen [13].
Bone aluminum staining revealed linear bone aluminum de-
posits in only three patients, 3, 4, and 10. In these patients,
aluminum deposits covered 15 to 42.6% of trabecular surfaces.
In three patients, only minimal traces of aluminum deposits
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Table 4. Individual static parameters of trabecular iliac bone in hemodialyzed patients before (A) and after (B) parathyroidectomy
Patient
no.
Before/after
PTX
TBV,
%
TRS,
%
OCI,
mm2
TOy,
%
TOS,
%
TIOS OblS,
%
A1S,
%
Fibrosis
I A 28.0 15.7 4.80 13.5 54.1 24.9 23.6 0 + + +
B 30.0 1.8 0 9.8 87.4 11.2 1.8 0 0
2 A 16.1 23.7 6.67 13.2 63.0 22.0 41.9 0 + + +
B 15.1 9.0 0.85 10.5 78.4 13.3 13.4 0 +
3 A 15.9 21.3 1.15 7.2 36.9 19.5 5.2 15.0 + +
B 9.6 11.0 0.40 7.8 49.0 15.6 4.9 32.9 0
4 A 35.2 15.6 5.82 19.0 73.1 25.9 30.9 42.6 + + +
B 26.2 7.4 0.51 10.0 45.4 22.0 15.8 55.1 0
5 A 18.2 23.5 1.92 6.6 31.4 21.1 14.9 0 + + +
B 20.8 17.3 0.66 4.9 30.0 16.3 4.6 11.0 +
6 A 17.1 12.2 3.14 6.9 33.5 20.5 18.7 0 + +
B 16.3 3.8 0.31 3.2 20.3 15.8 3.1 Traces +
7 A 28.9 10.2 1.10 6.0 25.4 23.5 9.7 Traces 0
B 24.4 6.0 0.51 4.8 30.0 16.0 4.2 Traces 0
8 A 30.0 11.1 1.82 5.2 31.4 19.7 17.0 Traces 0
B NM 1.3 0 2.2 11.3 19.5 1.0 6.2 0
9 A 25.3 18.3 4.41 18.9 68.0 27.0 39.2 Traces + +
B 25.0 13.4 1.50 1.9 15.6 12.1 5.2 24.3 0
10 A 19.0 15.6 2.24 9.8 52.6 18.6 19.3 21.7 +
B 28.4 3.2 0.31 1.9 20.0 9.5 1.3 29.1 0
Abbreviations: PTX, parathyroidectomy; TBV, trabecular bone volume; TRS, trabecular resorption surfaces; OC1, osteoclast number; TOy,
trabecular osteoid volume; TOS, trabecular osteoid surfaces; TIOS, thickness index of osteoid seams; OblS, osteoblastic surfaces; NM, not
measurable.
Table 5. Individual dynamic parameters of iliac bone in hemodialyzed patients before (A) and after (B) parathyroidectomy
.Patient
no.
Before/after
PTX
DLS
%
DLOS
%
TLS
%
Trab CR Cort CR BFR, tissue BFR, BMU
hrpinI24 p3/2/24 hr
A
B
14.3
1.1
26.4
1.3
52.3
26.3
0.64
0.20
0.73
0.64
0.33
0.05
0.62
0.06
.,
A 26.5 42.1 51.7 1.27 1.77 0.66 1.04
B 7.1 9.1 13.4 1.30 0.80 0.17 0.22
A
B
3.7
3.4
10.0
6.8
25.3
10.4
1.09
0.84
—
1.19
0.28
0.09
0.77
0.18
A
B
NM
7.6
NM
16.7
NM
15.4
0.77
0.78
1.10
0.77
NM
0.12
NM
0.26
, A 15.3 48.7 26.5 0.77 0.85 0,20 0.65
B 3.9 13.0 7,2 0.63 — 0.05 0.15
6 AB
21.6
2.7
64.5
13.3
32.1
8.4
0.74
0.57
1.03
0.54
0.24
0.05
0.71
0.24
'
A
B
4.5
2.5
17.7
8.3
14.5
7.6
0.50
0.30
—
—
0.07
0.02
0.29
0.08
8 AB
20.0
0.5
63.7
4.4
30.1
1.0
0.99
NM
1.17
0.56
0.30
NM*
0.95
NM
A
B
34.0
1.9
50.0
12.2
71.0
12.0
0.84
0.71
0.74
0.72
0.60
0.09
0.88
0.55
10 AB
16.0
0
30.4
0
29.0
0
1.38
NM
1.28
—
0.40
NM*
0.76
NM
Abbreviations: PTX, parathyroidectomy; DLS, double-labeled surfaces; DLOS, double-labeled osteoid surfaces; TLS, total-labeled surfaces;
Trab CR, trabecular calcification rate; Cort CR, cortical calcification rate; BFR (tissue), bone formation rate at the tissue level; BFR (BMU), bone
formation rate at the basic multicellular level; NM, not measurable (*, because of the marked reduction of TLS).
mainly localized inside the calcified bone were shown by the patients, 1 to 8, whose serum iPTH concentrations before PTX
histochemical method. These aluminum traces were not quan-
tifiable because they were too tiny and difficult to delineate. In
four patients, bone aluminum staining was negative.
Correlation between biochemical and histomorphometric pa-
rameters before parathyroidectomy. No significant correlation
was found between histomorphometric parameters of bone
formation and serum alkaline phosphatase levels or aluminum
levels. A correlation between serum iPTH levels and
histomorphometric parameters was established in only eight
were measured with the OP 47 antiserum. No significant
correlation was found between iPTH values and resorption
surfaces (r = 0.45) or osteoclast number (r = 0.69). The latter
correlation narrowly missed statistical significance.
Osteoblastic surfaces were correlated with iPTH (r =0.76, P <
0.05) as were osteoblastic osteoid surfaces (r = 0.81) and total
labeled surfaces (r = 0.82). Serum iPTH level was also cor-
related with bone formation rate at the tissue level (r =0.86, P
<0.05, Fig. 1) and at the BMU level (r = 0.79, P < 0.05).
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Table 6. Mean values (±sD) of histomorphometric parameters before and after parathyroidectomy (PTX) in hemodialyzed patients
Before PTX
(N = 10)
After PTX
(N = 10) Control values
TBV, % 23.4 6.9 21.8 6.8 21.2 5.1 (N = 143)
TRS, % 16.7 4.9 7•4 53C 3.6 1.1 (N = 130)
OCI, mm2 3.3 2.0 0.5 0.4C 0.2 0.ld
TOy, % 10.6 5.2 5.7 35C 2.7 1.8 (N = 72)
TOS, % 46.9 17.3 38.8 26.3 14.2 7.7 (N = 72)
TIOS 22.3 2.9 15.1 3.8C 18.6 4.1 (N = 72)
OblS, % 22.0 12.0 5.5 5.0 5.1 3.Od
CRtra, /.Un/24 hr 0.9 0.3 0.7 0.3k (N = 8) 0.7 0.1 (N = 42)
pmI24 hr 1.1 0.3 (N = 8) 0.8 0.2a (N = 7) No comparable normal data
DLS, % 17.3 9.7 (N = 9) 3.1 2.6C No comparable normal data
DLOS, % 39.3 19.4 (N = 9) 8.5 5•5C No comparable normal data
TLS, % 37.0 17.6 (N = 9) 10.2 7•5C 13.9 5.8c (N = 13)
TLOS, % 82.4 17.9 (N = 9) 27.8 21.OC No comparable normal data
BFRTi,,UC, j.un3/sm2/24 hr 0.3 0.2 (N = 9) 0.08 0.05" (N = 8) 0.09 0.05c (N = 13)
BFRBMU, i.tm3In2/24 hr 0.7 0.2 (N = 9) 0.2 0.2" (N = 8) No comparable normal data
Abbreviations: TBV, trabecular bone volume; TRS, total osteoclastic resorption surfaces; OCI, osteoclast number; TOy, trabecular osteoid
volume; TOS, trabecular osteoid surfaces; TIOS, thickness index of osteoid seams; ObiS, osteoblastic surface; CRtb, trabecular calcification rate;
CR0,,, cortical calcification rate; DLS, double-labeled surfaces; DLOS, double-labeled osteoid surfaces; TLS, total-labeled surfaces; TLOS, total
labeled osteoid surfaces; BFR,15,,,, bone formation rate at tissue level; BFRBMU, bone formation rate at basic multicellular unit.
The value is different from initial values; significant at: a P < 0.05; b P = 0.01; C P < 0.01.
d Data were obtained from Rasmussen and Bordier [10].
C Data were obtained from Nielsen, Melsen, and Christensen [13].
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Fig. 1. Changes in the bone formation rate (BFR) at the tissue-level
before (0) and after (•) parathyroidectomy (PTX) in hemodialyzed
patients. BFR tissue (x) before PTX is significantly correlated with
iPTH (y): y = 3544x — 124, (r = 0.86, P < 0.05)
At the time of the second bone biopsy (after PTX)
Biochemistry (Tables 2 and 3). As expected after a successful
PTX, serum calcium and phosphorus levels dropped dramati-
cally except in patients 3, who underwent a subtotal PTX, and
7, who underwent a total PTX with an autograft. Contemporary
to the second biopsy, SCa, however, had returned to normal
values by means of the calcium and vitamin D supplementation.
Serum phosphorus also rose progressively and was controlled
by aluminum hydroxide administration. When compared with
the pre-PTX values, SCa and SP at the time of the second bone
biopsy were not significantly different.
Serum alkaline phosphatase levels decreased significantly (P
<0.05). Serum iPTH levels decreased in all patients (P < 0.01)
and were within the normal range in three patients after PTX.
Serum aluminum levels decreased in seven out of nine patients
but post-PTX values for serum aluminum levels were not
significantly different from pre-PTX values.
Bone histomorphometry (Tables 4, 5, and 6). Parathyroidec-
tomy was associated with a highly significant reduction in
resorption parameters: Resorption surfaces decreased from an
initial mean value of 16.7 4.9% to 7.4 5.3% (P < 0.01) and
the osteoclast number dropped from an initial mean value of
3.31 2.00/mm2 to 0.51 0.44/mm2 (P < 0.01). When
compared to control values, post-PTX resorption surfaces
remained significantly increased (P < 0.05) being consistent
with a persistent HPT.
There was also a significant reduction in osteoid volume (both
relative and absolute OV, P < 0.01). Osteoid surfaces did not
change significantly, but osteoblastic surfaces decreased signifi-
cantly (P < 0.01). The thickness index of osteoid seams
decreased in all patients (P < 0.01) to normal or low values
indicating the absence of osteomalacia. Dynamically, both
cortical and trabecular calcification rates decreased signifi-
cantly (P < 0.05). The calcification rate values remained in the
normal range except in patients 1 and 7; patient 7 already
exhibited evidence of osteomalacia with a low calcification rate
before PTX. Both double- and single-labeled surfaces de-
creased significantly (P < 0.01) as well as the single- and
0
0.1 0.2 0.3 0.4 0.5 0.6
BFRt,=,e, p.m3/p.m2/24 hr
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between 1MPTH and the reduction in BFRtissue and BFRBMU
were not significant (r — 0.83 and r = 0.63, respectively) likely
because of the small number of patients (N = 6).
Discussion
Fig. 2. Undeca1ëifiTeffons of transiliac bone biopsy taken from
patient 10, 10 months after the parathyroidectomy. There are very few
thin osteoid seams (Ost) as shown in the A (Goidner's staining method)
despite aluminum deposits (Al) at the neutral surfaces (arrows) and at
the cement lines. B Methylene blue and Aluminon® staining procedure.
double-labeled osteoid surfaces. Consequently, bone formation
rates at the tissue level (Fig. 1) and at the BMU level decreased
significantly (P < 0.01). Bone marrow fibrosis, when present,
regressed in all patients.
When compared to normal values, osteoid surfaces and
osteoid volume remained significantly increased (P < 0.01), but
the thickness index of osteoid seams was significantly lower (P
<0.01). Dynamically, the BFR tissues were not different from
normal values, but was low or in the lower range of normal
values in six patients. In addition, the total labeled osteoid
surfaces were below the normal range reported in several
studies [13, 16].
On post-PTX biopsy specimens, the aluminum-covered sur-
faces increased in the three patients who already had positive
stainable bone aluminum before parathyroidectomy. In three
additional patients who had no or minimal aluminum traces
before PTX, the bone aluminum staining was positive after
PTX. In the six patients with stainable bone aluminum after
PTX, there was no significant correlation between the extent of
aluminum surfaces and the parameters of bone formation.
Correlations between changes in parathyroid function and
changes in histomorphometric parameters following PTX
The reduction in iPTH values (iPTH = iPTH before —iPTH
after PTX) was correlated with both the decrease in the
osteoclast number (r = 0.89, P < 0.05), the decrease in
resorption surfaces (r = 0.79, P < 0.05), and the reduction of
the osteoblastic surfaces (r = 0.96, P < 0.01). Correlations
The histomorphometric analysis of iliac bone biopsy speci-
mens taken before parathyroidectomy from hemodialyzed pa-
tients confirms previous investigations showing that hyper-
parathyroidism is characterized by a marked increase in bone
turnover with an increase in both resorption and formation
parameters. This has been found both in primary HPT [17—19]
and secondary HPT of chronic renal failure [201. The main
effect of PTH on bone consists of increasing the number of new
basic multicellular unit [21], that is, the number of functional
cells responsible for the turnover of a remodeling unit. Accord-
ing to the concept of Takahashi et al [22], firstly there is a rise
in the number of osteoclasts and consequently in the resorption
surfaces at the tissue level. Because of the coupling between
resorption and formation processes [23, 24], the increased bone
resorption is associated with an increase in bone formation
parameters as clearly shown by the correlation between the
osteoclast number and the osteoblastic surfaces found in this
study and in others [15, 25, 26]. Consequently, bone formation
rate at the tissue level is markedly increased in hemodialyzed
patients suffering from severe HPT without osteomalacia [13,
16, 26, 27]. Identically, at the BMU level, bone formation rate
is increased since the calcification rate is elevated and the
percentage of active osteoid seams is in the normal range
according to the values already reported [13, 16]. At the cellular
level, the activity of individual osteoblasts is also elevated since
the calcification rate is higher than normal [28—30]. Whether this
increased bone formation at the cellular level is directly or
indirectly related to the increased PTH secretion remains
uncertain because this is not found in patients with primary
HPT; the calcification rate in these patients was decreased
[17—19]. This increased bone formation at the tissue level, BMU
level, and cellular level is reflected by the rise in serum alkaline
phosphatase level and explains the increased trabecular bone
volume frequently seen in uremic patients [7, 29].
Subtotal or total parathyroidectomy with autotransplantation
in the forearm is followed by a marked reduction in PTH
secretion. This reduction in the parathyroid activity is followed
by a rapid and severe drop in serum calcium and serum
phosphorus. However, two patients, one of them with
osteomalacia, failed to demonstrate a severe hypocalcemia
after parathyroidectomy. These two patients had the lowest
iPTH levels and the lowest numbers of osteoclasts on pre-PTX
bone biopsy specimens of our patient group. This agrees with
the results of Felsenfeld et al [31] who showed that the decrease
in serum calcium following parathyroidectomy was correlated
with the severity of hyperparathyroid bone lesions before
parathyroidectomy. In retrospect, parathyroidectomy should
not have been performed, at least in patient 7 who had
osteomalacia and minimal hyperparathyroid bone lesions. After
parathyroidectomy, there is a dramatic reduction in bone cell
population involved in bone remodeling, namely osteoclasts
and osteoblasts. At the tissue level, bone resorption is markedly
reduced as shown by the decrease in resorption surfaces and
the osteoclast number. This is also associated with a significant
reduction in the bone formation rate both at the tissue level and
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at the BMU level confirming the maintenance of the coupling
between bone formation and bone resorption. As shown in this
study, bone formation rate at the cellular level was also reduced
by PTX because both the thickness index of osteoid seams and
the calcification rate decreased. This clearly shows that indi-
vidual osteoblasts synthesize a smaller amount of bone than
they did prior to the PTX.
The regression of HPT bone lesions after PTX, however, is
incomplete in our patient group since resorption surfaces re-
mained significantly increased and the osteoclast number re-
mained elevated in six out of ten patients. This suggests that the
surgical reduction of parathyroid gland tissue might have in-
duced an insufficient regression of hyperparathyroid bone le-
sions or that the prolonged administration of calcium, vitamin D
compounds, and phosphate binders was not sufficient to pre-
vent the recurrence of HPT bone lesions.
In fact, on the basis of the persistence of increased resorption
parameters (resorption surfaces and osteoclast number) after
PTX, six patients still demonstrated a sustained activation of
bone remodeling and four patients had normal or low values for
resorption parameters. Among these four patients, three, 1, 6,
and 8, underwent a total PTX with autotransplantation, and
patient 10 had a subtotal PTX removing only two glands. This
shows that a subtotal PTX followed by a calcium and vitamin D
supplementation can normalize bone resorption as well as a
total PTX with autotranspiantation. When assessed by the
measurement of bone formation rate at the tissue level, the
bone remodeling after PTX was low or in the lower range of
normal values in six patients. Four did not exhibit evidence of
increased resorption parameters. In three of these latter pa-
tients, 6, 8, and 10, osteoid volume and osteoid surfaces were in
the normal range. In patient 1, however, osteoid volume and
osteoid surfaces were markedly increased but the osteoid seam
thickness remained normal. There was a dramatic decrease in
double-labeled surfaces and in the calcification rate, but wide
osteoid seams characteristic of osteomalacia did not develop
because of a parallel reduction of the bone matrix synthesis.
None of our patients showed evidence of osteomalacia, that is,
a combination of increased osteoid seam width and low calci-
fication rate as it has been reported after a parathyroidectomy
[6, 71. By March 1984, none of them had developed fractures.
Thus, the present study does not allow the ascertainment of
pathophysiological mechanisms of osteomalacia after PTX.
However, it is interesting to note that PTX is associated with a
marked reduction in plump osteoblasts and in both single and
double-labeled osteoid surfaces indicating that the amount of
mineralized bone per unit of osteoid surfaces is reduced. This
result, in addition to the fact that iPTH levels were correlated
with the percentage of osteoid surfaces showing tetracycline-
labels in uremic patients [13, 30], strengthens the assumption
that PTH is important in the activation of osteoblasts and the
mineralization process in dialyzed patients. Thus, parathyroid-
ectomy can lead to an inactive bone, so-called "aplastic bone"
[32]. Longitudinal studies of dialyzed patients with "aplastic
bone" lesions have shown that aplastic bone could change to
osteomalacia with time [32], and therefore, parathyroidectomy
might create a favorable condition to the development of low
turnover osteomalacia.
Hypoparathyroidism is possibly associated with osteoma-
lacia [331. Dialysis osteomalacia is also frequently associated
with a diminished secretion of PTH [34, 35]; patients suffering
from this condition show a decreased ability to restore plasma
calcium homeostasis during hypocalcemia induced by a dialysis
against a calcium-free dialysate [36, 37]. A low parathyroid
activity was apparently found after PTX in five osteomalacic
patients reported by Felsenfeld Ct al [6] and in two of the three
patients reported by Weinstein [7]. In our study, three patients
had serum iPTH values within the normal range at the time of
the second bone biopsy. They all demonstrated a low bone
turnover with low bone formation, but one patient only had an
increased osteoid volume and osteoid surfaces which was likely
the result of a defective mineralization. But morphological
evidence of osteomalacia with increased osteoid seam thickness
could not develop because of the marked depression of the bone
matrix apposition. No further bone biopsy could be performed
in this patient to know whether or not he developed histological
evidence of osteomalacia with increasing time.
Although the present study was not designed to provide a
systematic inquiry into the possible role of aluminum in the
bone changes following parathyroidectomy, it provided us the
opportunity to analyze bone biopsy specimens from patients
having histochemical evidence of aluminum overload before
parathyroidectomy. The responsibility of aluminum intoxica-
tion in the development of osteomalacia after PTX has been
proposed [38], but it is not yet demonstrated. The measurement
of the bone aluminum content or the histochemical staining of
bone aluminum deposits were not reported in the patients
developing osteomalacia after PTX [6, 7]. In the present study,
the bone aluminum content was not measured, but the bone
aluminum deposits were revealed by histochemical staining.
The extent of the trabecular surfaces covered with aluminum
deposits has been shown to be correlated with the bone
aluminum content measured by atomic absorption spectropho-
tometry [141. Therefore, it may be assumed that the staining
method gives a good estimate of the amount of aluminum in
bone. Three of our patients demonstrated a positive aluminum
staining on the biopsy specimens taken before PTX. In two
patients, the main source of aluminum was very likely the
dialysis water since water aluminum concentration was mark-
edly increased at the time of the PTX (115 and 66 pjg/liter in
patients 4 and 10, respectively). A treatment of dialysis water
by reverse osmosis was done 3 months after the PTX in patient
4, but the bone aluminum staining was still positive on the
second biopsy specimen taken after PTX. No water treatment
was applied to patient 10 whose serum aluminum level re-
mained markedly increased (400 pg/liter) at the time of the
second bone biopsy. At this time, the trabecular aluminum
surfaces were greater than they were prior to the PTX. How-
ever, there were no thick osteoid seams characteristic of
osteomalacia (Fig. 2), but no tetracycline-labeled surfaces were
seen indicating an inactive bone. In the third patient who had
stainable bone aluminum before parathyroidectomy (patient 3)
as well as in three additional patients, the extent of trabecular
surfaces covered with aluminum deposits also increased after
PTX. In our study, the aluminum concentration of the dialysis
water was not measured at regular and short intervals after the
parathyroidectomy and therefore an exposure to aluminum
from the water cannot be excluded in the patients, especially in
patient 9 who had high serum aluminum levels. In addition, all
these patients continued to receive aluminum hydroxide gels
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after the parathyroidectomy. Thus, it is not known whether this
increase in bone aluminum deposits after parathyroidectomy is
related to the persistence of the aluminum exposure, to the
decrease in bone remodeling induced by the parathyroidectomy
which could influence the aluminum deposition in bone or both
factors. On the other hand, the presence of an aluminum
overload in some patients could contribute to lowering bone
formation either by a direct effect of aluminum on the osteoblast
function or by a reduction of the PTH secretion by the remain-
ing parathyroid glands, as it has been shown in in vitro studies
[39, 401. Since there is good evidence in hemodialyzed patients
that aluminum could interfere with the mineralization, es-
pecially when hyperparathyroidism is lacking [411, it is reason-
able to assume that PTX may increase the risk of aluminum-
related bone disease. Until more information is obtained in this
respect, we must be very cautious with the bone aluminum
intoxication especially when a parathyroidectomy is planned.
Likewise, a strict follow-up of patients must be done concern-
ing the aluminum exposure of the patients after PTX.
Severe hypophosphatemia has been reported to be associated
with osteomalacia in hemodialyzed patients [421 and prolonged
hypophosphatemia may occur after PTX [43, 44]. Thus, its role
in the impairment of the mineralization process reported after
PTX has also been discussed, but evidence is not yet available
that this condition was present in patients developing OM after
PTX. In our study, none of our patients demonstrated pro-
longed hypophosphatemia after PTX, and the mean serum
phosphorus level at the time of the second bone biopsy was not
different from pre-PTX values.
In conclusion, this study confirms that subtotal as well as
total parathyroidectomy is effective for correcting severe bone
lesions of hyperparathyroidism in hemodialyzed patients. PTX
strongly reduces the number of osteoclasts and resorption
surfaces but, in the same way, markedly reduces bone forma-
tion at the tissue, BMU, and cellular levels. After PTX, no
evidence of osteomalacia was found in our patients even in
those having bone aluminum deposits. Bone formation rate at
the tissue level was low or in the lower range of the normal
values in six patients, one of whom had a defective mineraliza-
tion. An excessive reduction in PTH secretion leading to a
dramatic reduction in the number and in the individual activity
of osteoblasts provides evidence for an "inactive bone." This
must be considered because it might contribute to increase the
deleterious effect of aluminum on bone. However, the risk for a
patient to develop low turnover osteomalacia after PTX seems
to be reasonably minimized by
• making sure of the absence of aluminum intoxication and
osteomalacia before PTX with a bone biopsy,
• avoiding excessive aluminum exposure after PTX, and
• ensuring that an excessive surgical reduction of the
parathyroid glands is avoided.
Reprint requests to Dr. S. A. Charhon, INSERM Unite 234, Faculté
Alexis Carrel, rue Guillaume Paradin, 69008 Lyon, France
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